Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer

Background: Previous studies have been conducted to reveal the relationship between androgen receptor CAG polymorphism and risk of prostate cancer, yet the results were elusive and controversial. Thus, this meta-analysis was performed to clarify this association. Methods: To obtain the relevant available studies, online databases PubMed, Embase, and Web of science were searched until September 1st, 2016. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of such association. Subgroup analyses were conducted based on ethnicity and source of controls. Moreover, Begg's funnel plots and Egger's linear regression test were conducted to test the publication bias. Results: Overall, our results enrolled 51 studies indicated that significant increased risk of prostate cancer was associated with androgen receptor CAG polymorphism (OR  =  0.77, 95% CI: 0.67–0.89). In addition, compared with CAG repeat <20, 22, carriers of ≧20, 22 repeats had decreased risk of prostate cancer (cut-off point  =  20: OR  =  0.27, 95% CI: 0.13–0.52; cut-off point  =  22: OR  =  0.82, 95% CI: 0.70–0.97). However, when cut-off point  =  23, no significant result was detected in such association (pooled OR  =  0.88, 95% CI: 0.63–1.24). When cut-off point is 22, the results were positive only in Asian population (OR  =  0.53, 95% CI: 0.32–0.89) in the subgroup analysis by ethnicity. Besides, when the studies were stratified by source of controls, the results were not significant in both the subgroup of population-based controls and hospital-based controls. Conclusions: This meta-analysis suggested the carriers of short polymorphic CAG repeats might increase susceptibility to prostate cancer, which held potential as a detecting marker of the risk of prostate cancer.

[1]  W. Niu,et al.  The CAG repeat polymorphism of androgen receptor gene and prostate cancer: a meta-analysis , 2011, Molecular Biology Reports.

[2]  C. Cheng,et al.  Shorter CAG repeats in androgen receptor and non-GG genotypes in prostate-specific antigen loci are associated with decreased risk of benign prostatic hyperplasia and prostate cancer. , 2008, Cancer letters.

[3]  J. Cauley,et al.  Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[5]  David V Conti,et al.  Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR , 2004, The Prostate.

[6]  J. Stanford,et al.  Polymorphisms in the androgen receptor and the prostate–specific antigen genes and prostate cancer risk , 2005, The Prostate.

[7]  I. Thompson,et al.  Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. , 2002, The Journal of urology.

[8]  E. Thompson,et al.  Performing the exact test of Hardy-Weinberg proportion for multiple alleles. , 1992, Biometrics.

[9]  K. Cooney,et al.  The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study , 2008, Journal of Human Genetics.

[10]  O. Cussenot,et al.  Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways , 2001, Cancer.

[11]  Ruth Etzioni,et al.  Androgen receptor polymorphisms and the incidence of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  C. Sternberg,et al.  Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer , 2015, Translational andrology and urology.

[13]  A. DeMarzo,et al.  The diet as a cause of human prostate cancer. , 2014, Cancer treatment and research.

[14]  J. Carpten,et al.  Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk , 2002, Human Genetics.

[15]  M. Forrest,et al.  Association between hormonal genetic polymorphisms and early-onset prostate cancer , 2005, Prostate Cancer and Prostatic Diseases.

[16]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[17]  G. Muto,et al.  Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. , 2011, Cancer epidemiology.

[18]  J. Schleutker,et al.  Androgen receptor CAG polymorphism and prostate cancer risk , 2002, Human Genetics.

[19]  H. Sim,et al.  Changing demography of prostate cancer in Asia. , 2005, European journal of cancer.

[20]  L. Torres-Sánchez,et al.  Androgen receptor CAG polymorphism and sporadic and early-onset prostate cancer among Mexican men , 2016, Journal of Human Genetics.

[21]  V. Panz,et al.  Tandem CAG repeats of the androgen receptor gene and prostate cancer risk in black and white men , 2001, Endocrine.

[22]  A. López-Cortés,et al.  Positive association of the androgen receptor CAG repeat length polymorphism with the risk of prostate cancer. , 2016, Molecular medicine reports.

[23]  D. Berney,et al.  Involvement of different mechanisms for the association of CAG repeat length polymorphism in androgen receptor gene with prostate cancer. , 2014, American journal of cancer research.

[24]  W. Vogel,et al.  (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French–German population , 1999, European Journal of Human Genetics.

[25]  Vettriselvi Venkatesan,et al.  South Indian men with reduced CAG repeat length in the androgen receptor gene have an increased risk of prostate cancer , 2006, Journal of Human Genetics.

[26]  W. Willett,et al.  Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era , 2005, Cancer Epidemiology Biomarkers & Prevention.

[27]  Kazuhiro Ito,et al.  Polymorphisms in the AR and PSA Genes as Markers of Susceptibility and Aggressiveness in Prostate Cancer , 2010, Cancer investigation.

[28]  Xiaolei Zhai,et al.  Correlation study between the polymorphism of repetitive sequence in gene CAG of androgen receptor and the occurrence and progression of prostate cancer. , 2014, Asian Pacific journal of tropical medicine.

[29]  J. Stanford,et al.  Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. , 1997, Cancer research.

[30]  F. Mostofi,et al.  Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  G. Cancel-Tassin,et al.  Association between estrogen and androgen receptor genes and prostate cancer risk. , 2009, European journal of endocrinology.

[32]  E. L. Miller,et al.  Polymorphic repeats in the androgen receptor gene in high‐risk sibships , 2001, The Prostate.

[33]  Rebecca L. Siegel Mph,et al.  Cancer statistics, 2016 , 2016 .

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[35]  M. Modarressi,et al.  Are GSTM1, GSTT1 and CAG Repeat Length of Androgen Receptor Gene Polymorphisms Associated with Risk of Prostate Cancer in Iranian Patients? , 2011, Pathology & Oncology Research.

[36]  H. Grönberg,et al.  Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway , 2006, The Prostate.

[37]  I. Thompson,et al.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. , 2010, The Journal of urology.

[38]  A. Wolk,et al.  Lifestyle and dietary factors in prostate cancer prevention. , 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[39]  P. Wieacker,et al.  Significance of the CAG repeat length in the androgen receptor gene (AR) for the transactivation function of an M780I mutant AR , 1999, Human Genetics.

[40]  R. Kronmal,et al.  Genetic Susceptibility to Prostate Cancer: Prostate-specific Antigen and its Interaction with the Androgen Receptor (United States) , 2006, Cancer Causes & Control.

[41]  M. Nagai,et al.  Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population. , 2003, Cancer detection and prevention.

[42]  M. Simoni,et al.  Variation in CAG and GGN repeat lengths and CAG/GGN haplotype in androgen receptor gene polymorphism and prostate carcinoma in Nigerians , 2011, British journal of biomedical science.

[43]  Y. Bayazıt,et al.  Evaluation of the effects of androgen receptor gene trinucleotide repeats and prostate-specific antigen gene polymorphisms on prostate cancer. , 2012, Genetics and molecular research : GMR.

[44]  J. Batra,et al.  Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population. , 2012, Genetic testing and molecular biomarkers.

[45]  C. Friedenreich,et al.  Case–control study of lifetime alcohol intake and prostate cancer risk , 2013, Cancer Causes & Control.

[46]  C. Krausz.  An encore for the repeats: new insights into an old genetic variant. , 2012, The Journal of clinical endocrinology and metabolism.

[47]  P. Kantoff,et al.  The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer. , 1998, Biochimica et biophysica acta.

[48]  J. Manola,et al.  Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. , 2004, Clinical prostate cancer.

[49]  K. Thangaraj,et al.  Is there an inter-relationship between prostate specific antigen, kallikrein-2 and androgen receptor gene polymorphisms with risk of prostate cancer in north Indian population? , 2007, Steroids.

[50]  K. Thangaraj,et al.  Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population? , 2005, Clinical genetics.

[51]  Yong-jie Lu,et al.  Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes. , 2013, American journal of cancer research.

[52]  Kazuhiro Suzuki,et al.  Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. , 2006, Cancer detection and prevention.

[53]  R. Eeles,et al.  Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival , 1999, International journal of cancer.

[54]  H. Grönberg,et al.  Links between genetic and environmental factors and prostate cancer risk , 1999, The Prostate.

[55]  G. Coetzee,et al.  Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. , 2000, Cancer research.

[56]  J. Benichou,et al.  Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. , 2000, Cancer research.

[57]  H. Ostrer,et al.  How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[58]  G. Coetzee,et al.  Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.

[59]  P. Söderkvist,et al.  Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. , 2006, European journal of cancer.

[60]  S. Piantadosi,et al.  Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  G. Coetzee,et al.  Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. , 2000, Human molecular genetics.

[62]  M. Marberger,et al.  Polymorphic CAG repeats in the androgen receptor gene, prostate-specific antigen polymorphism and prostate cancer risk. , 2002, Carcinogenesis.

[63]  Ali Amin Al Olama,et al.  The genetic epidemiology of prostate cancer and its clinical implications , 2014, Nature Reviews Urology.

[64]  G. Coetzee,et al.  The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. , 1995, Cancer research.

[65]  P. Kantoff,et al.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Ming-Tsang Wu,et al.  Androgen receptor gene polymorphism and prostate cancer in Taiwan. , 2003, Journal of the Formosan Medical Association = Taiwan yi zhi.

[67]  M. Loda,et al.  Androgen Receptor CAG Repeat Polymorphism and Risk of TMPRSS2:ERG–Positive Prostate Cancer , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[68]  P. Spritzer,et al.  Polymorphic CAG and GGC Repeat Lengths in the Androgen Receptor Gene and Prostate Cancer Risk: Analysis of a Brazilian Population , 2008, Cancer investigation.

[69]  M. Menon,et al.  Effect of a short CAG (glutamine) repeat on human androgen receptor function , 2004, The Prostate.

[70]  Raghu Kacker,et al.  Random-effects model for meta-analysis of clinical trials: an update. , 2007, Contemporary clinical trials.

[71]  W. Willett,et al.  Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study , 2014, Cancer Causes & Control.